Biotech company Immunicom, which has developed a non-pharmaceutical, late-stage cancer treatment, has raised $11 million in a Series B investment round. Several private equity family offices participated in the round, increasing Immunicom’s overall capital raised to $20 million. The San Diego-based company won FDA breakthrough device designation in 2018 for its Immunopheresis therapy, which is […]